Hodgkin Lymphoma focusing on reducing radiotherapy, while maintaining the highest possible cure rate

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Advances in myeloma

ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma

President's overview of ASCO 2012

Drug shortage impact on cancer care and efforts to resolve the issue

Patient perspective on drug shortages

Recommendations for averting drug shortages

FDA's comments on drug shortages

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma

Increased risk of breast cancer among young women treated with radiation as a child

New MEK inhibitor, trametinib, improves survival in advanced melanoma